Predictions
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€72.70
11.08.17
11.08.17
€110.00
23.10.17
23.10.17
-37.14%
23.10.17
23.10.17
Nanobiotix
Start price
Target price
Perf. (%)
€20.70
03.07.17
03.07.17
€22.00
19.12.17
19.12.17
-38.60%
19.12.17
19.12.17
Could be worthwhile Investment >10% per year
Nanobiotix
Start price
Target price
Perf. (%)
€20.70
03.07.17
03.07.17
€22.00
19.12.17
19.12.17
-38.60%
19.12.17
19.12.17
Could be worthwhile Investment >10% per year
Groupe Partouche S.A.
Start price
Target price
Perf. (%)
€29.15
29.06.17
29.06.17
€40.00
23.10.17
23.10.17
13.58%
23.10.17
23.10.17
Groupe Partouche S.A.
Start price
Target price
Perf. (%)
€29.15
29.06.17
29.06.17
€40.00
23.10.17
23.10.17
13.58%
23.10.17
23.10.17
Rémy Cointreau S.A.
Start price
Target price
Perf. (%)
€101.30
09.06.17
09.06.17
€120.00
04.10.17
04.10.17
3.90%
04.10.17
04.10.17
EssilorLuxottica SA
Start price
Target price
Perf. (%)
€118.75
05.06.17
05.06.17
€130.00
18.05.18
18.05.18
1.16%
18.05.18
18.05.18
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Future proof or reliable business model
Akka Technologies
Start price
Target price
Perf. (%)
€41.74
06.05.17
06.05.17
€44.55
24.05.17
24.05.17
6.73%
24.05.17
24.05.17
Could be worthwhile Investment >10% per year
Montagne et Neige Développement S.A.
Start price
Target price
Perf. (%)
€250.00
15.02.17
15.02.17
€150.00
16.02.17
16.02.17
-6.80%
16.02.17
16.02.17
Could be worthwhile Investment >10% per year
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€63.11
10.02.17
10.02.17
€100.00
10.08.17
10.08.17
20.42%
10.08.17
10.08.17
Unibail-Rodamco-Westfield NV
Start price
Target price
Perf. (%)
€212.90
02.02.17
02.02.17
€300.00
15.06.17
15.06.17
9.96%
15.06.17
15.06.17
DBV Technologies S.A.
Start price
Target price
Perf. (%)
€60.50
09.08.16
09.08.16
€100.00
09.02.17
09.02.17
3.16%
09.02.17
09.02.17
GenKyoTex S.A.
Start price
Target price
Perf. (%)
€44.70
15.06.16
15.06.16
€50.00
16.12.16
16.12.16
-40.72%
16.12.16
16.12.16
Could be worthwhile Investment >10% per year